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E-mail: fulvio.mavilio@unimore.itReplication-defective retroviral vectors have been used for
more than 25 years as a tool for efficient and stable insertion
of therapeutic transgenes in human cells. Patients suffering
from severe genetic diseases have been successfully treated by
transplantation of autologous hematopoietic stem-progenitor
cells (HSPCs) transduced with retroviral vectors, and the first
of this class of therapies, Strimvelis, has recently received mar-
ket authorization in Europe. Some clinical trials, however, re-
sulted in severe adverse events caused by vector-induced
proto-oncogene activation, which showed that retroviral vec-
tors may retain a genotoxic potential associated to proviral
integration in the human genome. The adverse events sparked
a renewed interest in the biology of retroviruses, which led in a
few years to a remarkable understanding of the molecular
mechanisms underlying retroviral integration site selection
within mammalian genomes. This review summarizes the cur-
rent knowledge on retrovirus-host interactions at the genomic
level, and the peculiar mechanisms by which different retrovi-
ruses, and their related gene transfer vectors, integrate in, and
interact with, the human genome. This knowledge provides the
basis for the development of safer and more efficacious retro-
viral vectors for human gene therapy.
Integration in the genome of a host cell is a key step in the life cycle of a
retrovirus, allowing stable transmission of the viral genome to the host
cell progeny and persistent viral gene expression. Retroviral integration
is a non-random process whereby the viral RNA genome, reverse tran-
scribed into double-stranded DNA and assembled in a pre-integration
complex (PIC), associates to the host cell chromatin and integrates in
its proviral form in the genome through the activity of the viral inte-
grase (IN), a specialized protein encoded by the viral pol gene.1 Early
studies on viral integration were based on in vitro models, which iden-
tified several physical factors playing a role in the process, such as
nucleosome-induced DNA bending or steric hindrance by DNA-bind-
ing proteins. In vivo, however, viral integration is an active process
involving mainly cellular and viral players that have been, and still
are, extensively investigated. When the complete sequence of the ge-
nomes of several mammals, including humans, became available,
PCR-based methods were developed to amplify, clone, and sequence
the junctions between proviral and host genome,2,3 with the scope of
mapping proviruses on genomic DNA and understanding the rules
governing the integration process. Thanks to the spectacular develop-
ment ofDNA sequencing technology, ligation-mediated (LM) or linear
amplification-mediated (LAM) PCR have been progressively refined,Molecular Therapy: Methods
This is an open access article under the CC BY-NCallowing extensive mapping of viral integration sites (ISs) in mamma-
lian genomes in a quantitative fashion.
The first pioneering studies showed that retroviruses select their
genomic target sites in a sequence-independent manner, with prefer-
ences for transcribed genes in the case of the HIV3 or gene promoters
in the case of the Moloney murine leukemia virus (MLV).4 More
recently, massive parallel sequencing has greatly increased the resolu-
tion of integration maps, while genome-wide association with genetic
and epigenetic annotations of the human genome provided crucial
clues to the understanding of the molecular determinants of target
site selection. In summary, these studies revealed that each retrovirus
has a unique and peculiar pattern of integration within mammalian
genomes, which is faithfully reproduced by the gene transfer vectors
derived thereof. The non-randomness of viral integration patterns
has significant implications in terms of biosafety for gene therapy
applications.
Retroviruses Have Different Integration Preferences
Retroviruses are divided into seven genera (alpha-, beta-, gamma-,
delta-, and epsilon-Retroviridae, Spumaviridae, and Lentiviridae),
and integration characteristics and preferences are known for at least
one member of each family, except for epsilon-retroviruses. Integra-
tion profiles have been defined for members of the lentivirus, spuma-
retrovirus, alpha-retrovirus, and gamma-retrovirus genera. Not
surprisingly, the extent of available scientific knowledge on target
site selection and its determinants directly reflects the clinical rele-
vance of each retrovirus type, thus the HIV and MLV integration
profiles are the most extensively characterized.
Based on IS preferences, retroviruses can be classified in roughly three
groups: MLV, foamy virus (FV), and human T cell leukemia virus
(HTLV), which integrate preferentially around transcription start
sites (TSSs) and in transcriptional regulatory elements; HIV and sim-
ian immunodeficiency virus (SIV), which preferentially target tran-
scribed sequences; and avian sarcoma-leucosis virus (ASLV), which
shows little preference for any genomic feature. The different integra-
tion patterns and propensity for specific genomic characteristics indi-
cate the involvement of specific viral and cellular factors in the& Clinical Development Vol. 8 March 2018 ª 2017 The Authors. 31
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Figure 1. Differential Distribution of Gamma-
Retroviral and Lentiviral Integration Sites in the
Human Genome
MLV and HIV integration sites are differentially distributed
within the genome of a target cell. MLV preferred sites are
tightly clustered in and around active regulatory elements
(red arrows), whereas HIV preferred sites are spread
along transcription units, grouped in larger clusters (blue
arrows).
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roles in target site selection, genetic and biochemical evidence indi-
cate that the viral IN is the major viral determinant for most retrovi-
ruses. Unsupervised clustering of IS patterns and phylogenetic anal-
ysis of INs of six different retroviruses showed that global and local
IS preferences correlate with the sequence and/or structure of viral
INs,5 suggesting a strong correlation between target site selection
and viral evolution. The choice of a particular set of ISs is essential
for the viral fitness, because it influences not only the transcriptional
regulation the provirus will be subjected to, but also any interference
of the provirus with the host genome transcription.
Early studies demonstrated that DNA wrapped in nucleosomes is
a favored target for retroviral integration compared to naked
DNA,6–8 with the outward-facing DNAmajor groove being a preferred
target region.6 Much is known about the sequence constraints for
efficient integration of retroviruses. A dinucleotide CA is invariably
positioned exactly 2 bp from both ends of the viral termini. The
sequences extending up to 15 bp into the host DNA have significant
influence on integration efficiency, although retroviral integration is
not a sequence-specific process.4,9–12 The first analysis of hundreds of
HIV-1,MLV,ASLV, and SIV ISs inmammalian cells showedonly a sta-
tistically weak palindromic consensus centered on the virus-specific
duplicated target site sequence at the insertion sites.13 Later analysis
of larger datasets confirmed the occurrence of a weakly conserved
consensus at the ISs, not recurrent among different retroviruses and en-
riched when integration is studied on naked DNA in vitro, suggesting
that the consensus ismainly selected by the integrationmachinery itself,
most likely reflecting the spatial or energy requirements of the integra-
tion complex.9,14 These studies indicated that the linear DNA sequence
plays a minor role in the integration preferences of retroviruses, which
depends essentially on viral and cellular determinants and on their cell-
specific availability and interaction.32 Molecular Therapy: Methods & Clinical Development Vol. 8 March 2018Lentiviruses Target Transcribed Genes
HIV-1 is the best-characterized representative
of the Lentiviridae family, and the etiological
agent of AIDS. As soon as LM-PCR mapping
technology became available, the HIV integra-
tion pattern in the human genome was charac-
terized,3 showing a strong preference for gene
bodies, with up to 80% of the proviruses located
inside an active transcriptional unit. As a conse-
quence, HIV integration is influenced by thetranscription pattern of the target cell.3,15,16 Higher resolution maps
(up to 150,000 ISs) of the integration of HIV-1-derived lentiviral
vectors (LVs) were determined on human primary T cells14 and
CD34+ hematopoietic stem-progenitor cells (HSPCs).17 These studies
confirmed the HIV-1 preference for transcribed gene bodies, and re-
vealed a negative correlation between integration frequency and TSSs
and other typical feature of gene promoters, such as CpG islands,
G/C-rich sequences, DNase I hypersensitive sites, and clusters of
transcription factor binding sites (TFBSs).17,18 The association of
ISs with genome-wide maps of histone modifications revealed
another interesting feature: HIV-1 integration is strongly associated
to epigenetic marks of transcribed gene bodies such as H4K20me1,
H3K36me3, H2BK5me1, and H3K27me1.14,19,20 Interestingly,
HIV-1 has apparently evolved to avoid integrating into active tran-
scriptional regulatory regions, such as promoters and enhancers, as
defined by mono-, di-, and tri-methylation of H3K4 and histone hy-
peracetylation, or in genes controlling cell development and differen-
tiation, including proto-oncogenes17 (Figure 1). Genes targeted by
HIV-1 and LVs are mostly located in euchromatic regions in the
outer, membrane-proximal portion of the cell nucleus in close corre-
spondence with the nuclear pore, indicating a strong association be-
tween nuclear entry and integration mechanisms.21 On the contrary,
HIV and LVs strongly disfavor genes located in heterochromatic re-
gions marked by H3K27me3 and H3K9me3,14,17,20 including the nu-
clear lamin-associated heterochromatin.21 Transcriptionally active
genes are also disfavored if located centrally within the nucleus.21
Mechanisms of Lentiviral IS Selection: The Tethering Factors
HIV integration has been the first comprehensively described model
of target site selection based on protein-mediated tethering of the
retroviral PIC to the host cell chromatin. Several cellular proteins
have been isolated as physically bound to lentiviral PICs, and for
some of them the association occurs via direct interaction with the
A
B
Figure 2. HIV and MLV Pre-integration Complexes
Are Tethered to Chromatin by Different
Mechanisms
(A) The HIV pre-integration complex (PIC) is tethered to
transcribed gene regions (active gene body), marked by
specific histone modifications (H3K20me1, H3K27me1,
H3K36me3), by the LEDGF-P75 protein, which interacts
with the HIV integrase (IN) through an integrase-binding
domain (IBD) and with histones through its PWWP
domain. An AT-hook domain (AT) mediates interaction
with AT-rich DNA sequences on genomic DNA. (B) The
MLV PIC is tethered to transcriptionally active promoters
(left), enhancers, and super-enhancers (right) through
interaction of IN with bromodomain/extraterminal domain
proteins (BETs) bound to acetylated histones. A simplified
transcription initiation complex is shown on the promoter,
including the TATA-binding protein (TBP), the basal
transcription factors TFIIB and TFIIB, the Mediator com-
plex, and an elongating RNA polymerase II (Pol-II). A
simplified histone acetylation complex is shown on the
enhancer, including histone acetyl transferases (HATs)
and p300. Promoters (left) are marked by H3K4me2/3
histone modifications, histone acetylation, and the
H2AZ histone variant. Enhancers (right) are marked by
H3K4me1/2 and H3K27ac histone modifications.
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such as hRad1,22 components of chromatin remodeling complexes
such as INI123 and EED,24 the constitutive chromatin components
HMGI(Y),25 and most importantly, the lens epithelium-derived
growth factor (PSIP1/LEDGF/p75),26 a ubiquitously expressed nu-
clear protein tightly associated with chromatin throughout the cell
cycle. The role of LEDGF/p75 in mediating HIV infectivity has
been deeply investigated because of its tight interaction with the viral
IN and its role in stimulating the IN catalytic activity in vitro.27–29
LEDGF/p75 knockdown significantly reduces HIV-1 infectivity,
showing the functional role of this protein as the major cellular bind-
ing partner of HIV-1 IN.30,31
LEDGF/p75 was initially discovered as a human transcriptional coac-
tivator32 interacting with a number of cellular proteins, including
JPO2,31,33 Cdc7-activator of S-phase kinase (ASK),34 the transposase
pogZ,35 and menin, which links LEDGF/p75 with mixed-lineage leu-
kemia (MLL) histone methyltransferase, causing MLL-dependent
transcription and leukemic transformation.36 LEDGF/p75 belongs
to the hepatoma-derived growth factor-related protein (HRP) family,
which comprises five additional members—HDGF, HRP1-3, and
LEDGF/p52, an alternatively spliced, smaller isoform of LEDGF—
that, except for HRP2, lack the domains necessary to HIV-1 IN inter-
action.37 LEDGF/p75 is characterized by a conserved N-terminal
PWWP domain, a basic-type nuclear localization signal, two
AT-hook DNA binding motifs, and three highly charged regions
(CR1-3) that allow to tightly engage chromatin throughout the cell
cycle.29,38 The C-terminal region contains the IN-binding domain
(IBD), which directly interacts with HIV-1 IN.39 The N-terminal
PWWP domain is the key determinant for the site-selective associa-
tion of LEDGF/p75 with chromatin: HIV-1 ISs generated in the pres-Molecuence of PWWP domain-defective LEDGF/p75 mutants differ sub-
stantially from those generated in the presence of wild-type
LEDGF/p75.40
NMR structures of the LEDGF/p75 PWWP domain revealed two
distinct functional interfaces: a hydrophobic pocket that interacts
with the H3K36me3 histone tail and an adjacent basic interface
that non-specifically engages DNA.41,42 Interestingly, the LEDGF/
p75 PWWP domain exhibits low binding affinity for either an
H3K36me3 peptide or naked DNA, whereas it interacts tightly with
mononucleosomes containing an H3K36me3 analog, indicating
that cooperative binding of LEDGF/p75 with both the H3K36me3
tail and nucleosomal DNA is essential for its tight and site-selective
chromatin association.41 Indeed, mutations introduced in either the
hydrophobic pocket or the basic surface significantly compromised
the ability of LEDGF/p75 to both associate with chromatin and stim-
ulate HIV-1 integration.43 These findings collectively indicate that
LEDGF/p75-mediated tethering of lentiviral PICs to actively tran-
scribed genes provides IN with increased access to nucleosomal
DNA, which are the favored sites for integration both in vitro and
in infected cells6,14,44 (Figure 2A).
Interestingly, LEDGF/p75 fails to interact with INs from other retro-
viral genera.28,45,46 In vitro assays with purified INs have revealed that
LEDGF/p75 significantly stimulates the strand transfer activity of len-
tiviral but no other retroviral INs.27,29,39,47 Studies using LEDGF/p75
knockout cells revealed 5- to 80-fold defects in HIV-1 infectivity,
associated with 2- to 12-fold reduction in integration.48–51 Signifi-
cant inhibitory effects on HIV-1 replication were also observed in
cells engineered to express the LEDGF/p75 IBD domain only.52–54
LEDGF/p75 depletion and overexpression of dominant-interferinglar Therapy: Methods & Clinical Development Vol. 8 March 2018 33
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while selectively impairing provirus integration.
Genome-wide IS mapping provided additional evidence for the role of
LEDGF/p75 in the selectivity ofHIV-1 integration. LEDGF/p75 knock-
down significantly reduces integration into active genes,46,55while com-
plete knockout kills infectivity and dramatically changes integration
preferences, with a significant percentage of proviruses aberrantly
located near TSSs.48,49 Interestingly, chimeric LEDGF/p75 proteins
can retarget lentiviral integration: replacing the N-terminal PWWP
domain and AT hooks with a plant homeodomain redirects HIV-1
integration to TSSs,56 while the use of the chromobox homolog 1
(CBX1) and heterochromatin protein 1 (HP1) alpha chromatin-bind-
ing modules randomizes the integration pattern.56,57 Mapping of the
LEDGF/p75 chromatin-binding profile has revealed a preference for
binding active transcription units, which paralleled the enhanced
HIV-1 integration frequencies at these locations.58 Collectively, these
findings provide strong evidence that LEDGF/p75 tethers PICs to active
transcription units during HIV-1 integration.
Although LEDGF/p75 can potently stimulate HIV-1 IN catalytic
function in vitro,27,29,39,59,60 it is unclear whether it provides this func-
tion during natural virus infection. Normal levels of HIV-1 PIC activ-
ity are maintained in LEDGF/p75 knockout cells,49 indicating that
LEDGF/p75 may provide chromatin-tethering functions without
contributing to the formation of a catalytically active PIC. HIV-1 inte-
gration in transcription units is over-represented even in LEDGF/p75
knockout cells,48–50 suggesting a potential role of other cellular pro-
teins in the IS selection. In particular, HRP2 was closely investigated
because of its structural similarity with LEDGF/p75: in vitro assays
with purified proteins demonstrated that HRP2 tightly binds HIV-1
IN and significantly stimulates its catalytic function,39 although,
unlike LEDGF/p75, it does not bind chromatin throughout the cell
cycle.61 HRP2 depletion in cells containing normal levels of
LEDGF/p75 has no effect on HIV-1 infectivity or integration prefer-
ences,50,52,62,63 while depletion of both HRP2 and LEDGF/p75 re-
duces integration into active genes.63,64 The preference of HIV-1
for active genes remains greater than random even in LEDGF/
HRP2 double-knockout cells, suggesting that additional host factors
may play a role in HIV target site selection.63
Lentiviral Integration and Nuclear Import
A striking feature of HIV-1 integration is the preference for large
chromosomal domains, or hotspots, rich in active genes,3,17,65,66
which is not explained by the chromatin-binding characteristics of
LEDG/p75 or other chromatin interactors. Recent research on the
mechanisms of HIV active entry into the cell nucleus showed that
the interaction between the HIV PIC and components of the nuclear
import machinery plays a key role in tethering HIV integration to its
target chromatin, and pointed to nuclear topology as a major deter-
minant of target site selection. The nuclear pore complex (NPC) me-
diates docking and entry of the HIV into the nucleus through direct
interaction of the PIC with nucleoporins, thereby indirectly targeting
HIV integration to the pore-proximal chromatin regions.21,67 The34 Molecular Therapy: Methods & Clinical Development Vol. 8 March 2nuclear pore is associated with 10- to 500-kb macrogenomic domains
of open, actively transcribed chromatin. Knockdown of the Nup358/
RanBP2 or Nup153 components of the NPC impair HIV-1 nuclear
entry and bias integration toward a non-canonical pattern, indicating
that nuclear translocation and IS selection are coupled processes.68–70
Interestingly, HIV ISs in cells depleted of the chromatin-proximal
Tpr nucleoporin, which is not required for HIV nuclear entry,
are less associated with epigenetic marks of transcribed genes
(H3K36me3), as revealed by super-resolution microscopy.67 Interac-
tion with the NPC is mediated by the HIV-1 capsid protein (CA)
encoded by the Gag gene. Accordingly, chimeric HIV-1 viruses con-
taining the MLV Gag showed a reduced integration frequency into
gene-rich regions.69–71
To account for the overall integration preferences of HIV-1, a two-
step model has been proposed whereby NPC components direct
HIV-1 PICs toward membrane-proximal euchromatic regions of
high gene density, whereas LEDGF/p75 tethers the PIC to the tran-
scribed gene bodies within these regions.69,70 A recent study showed
that the integration hotspots are in fact located in close proximity to
the nuclear pore, and that the likelihood of integration into an active
gene is a function of its radial distance from the nuclear membrane21
(Figure 3). Because the topological organization of chromatin is cell
specific, integration hotspots vary from one cell type to another,21 re-
flecting their position with respect to the NPC. Hotspots are therefore
essentially generated by the topological organization of chromatin in
the cell nucleus, while the local preference for transcribed regions
within hotspots is actively determined by the PIC through its teth-
ering interactions primarily with LEDGF/p75 (Figure 3). Because
all the integration preferences are mediated by the protein compo-
nents of the PIC, LVs faithfully reproduce the integration character-
istics of parental HIV.
Gamma-Retroviruses Target Transcriptionally Active Promoters
and Enhancers
MLV belongs to the gamma-retrovirus family, historically known as
Oncoretroviridae since the discovery that viruses of this family can
transmit leukemia to newborn mice.72 Because of their relatively sim-
ple structure and efficiency in infecting hematopoietic cells, replica-
tion-defective MLV-based vectors were the first gene transfer tools
used in gene therapy for hematological disorders. The MLV integra-
tion profile has been extensively analyzed in HSPCs and other cell
types for many years, particularly after the occurrence of insertional
leukemia in patients treated for inherited immunodeficiencies.73,74
High-throughput sequencing technology recently extended the num-
ber of analyzedMLV ISs into the millions, providing deep insight into
the mechanism of MLV target site selection.18
Initial, low-resolution integration studies showed that MLV and
MLV-derived vectors had a modest bias for integration into active
genes with a peculiar distribution around TSSs, with 20% of inser-
tions landing 2.5 kb upstream or downstream of the +1 position of
target genes.4,15,16,65 Thus, gene promoters were considered for
some time as the major target of MLV integration. Later studies018
Figure 3. Overview of Lentiviral Nuclear Entry and
Integration
The lentiviral pre-integration complex (PIC) docks to and
passes through the nuclear pore via the interaction with
Nup153 and other nucleoporins, and integrates prefer-
entially in the euchromatic regions (in green) near the
nucleopores. The lentiviral PIC is then targeted to regions
marked by histone modifications specific of transcribed
gene (H3K36me3) through tethering operated by
LEDGFp75 (see Figure 2). The hot-cold color scale in-
dicates low (cold) and high (hot) probability of lentiviral
integration. IN, HIV-1 integrase; LAD, lamina-associated
domains; Nup153, nucleoporin 153. (Modified from
Marini et al., 2015.21)
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islands, DNase I hypersensitive sites, TFBSs, phylogenetically
conserved non-coding sequences, and binding sites for the p300/
CBP histone acetyl transferase, often predictive of cis-acting regulato-
ry elements.20,71,75 High-definition integration maps showed that re-
gions bound by the Pol-II basal transcriptional machinery, such as
core promoters, are protected from the MLV insertion,17,20 confirm-
ing that integration is directed to TF-bound transcriptionally active
elements and not simply to open chromatin regions. Genome-wide
integration and association studies showed that the MLV bias for
TSSs is just a consequence of a more general preference of MLV
PICs for active regulatory elements, particularly enhancers and
super-enhancers.17,18,76–78 High-resolution studies carried out in
human HSPCs and committed progenitors,17,18,78 T cells,20,79 and
keratinocytes77 indicated that MLV ISs are highly clustered and occur
almost exclusively in regions carrying epigenetic signatures of tran-
scriptionally active regulatory regions, such as acetylation of H3K27
and H3K9, and mono-, di- and tri-methylation of H3K4 (Figure 1).
Symmetrically, typical heterochromatic marks, such as H3K27me3
and H3K9me3, are significantly under-represented at these genomic
loci.14,17,20,76 As a consequence, the MLV integration pattern is
strongly cell specific and depends on the enhancer and promoter us-
age of any given cell type: all studies invariably showed a correlation
betweenMLV integration and gene expression levels,3,16,17,20,65,80 and
a significant bias toward functional categories such as developmental
regulation, cell growth, and cell differentiation.20,65,76,80,81 These inte-Molecular Therapy: Methodsgration characteristics suggest that oncoretrovi-
ruses may have developed a unique integration
strategy that, by coupling target site selection to
cell-specific gene regulation, maximizes the
chances of maintaining proviral expression in
the target cells. In addition, integration around
promoters and regulatory elements of cell
growth and differentiation may increase the
chances of inducing clonal expansion or trans-
formation, and ultimately favor viral propaga-
tion. This hypothesis is supported by recent
chromatic conformation capture studies
showing that MLV ISs co-localize in tridimen-sional clusters enriched for known cancer genes in the nucleus of
target cells,82 suggesting that MLV proviruses engage in long-range
chromatin interactions that may favor oncogene deregulation.
Mechanism of Gamma-Retroviral Target Site Selection
As for HIV, at least two determinants are involved in MLV target site
selection, the viral PIC and the host cell factors that tether it to chro-
matin. The viral determinants of MLV target site selection have been
extensively investigated by genetic and biochemical analysis. Early
studies indicated that an HIV-1 vector packaged with an MLV IN ac-
quires the MLV-specific bias for TSSs, CpG islands and TFBS-rich re-
gions,71,75 identifying the IN protein as the main viral determinant of
MLV target site selection. Given the preference for active transcrip-
tional regulatory elements, components of the basal RNA Pol-II tran-
scriptional machinery were obvious candidates as cell-derived teth-
ering factors. Early data indicated that the protein BAF (barrier to
autointegration factor) is physically associated to the MLV PICs.83
BAF was originally identified as an inhibitor of suicide integration
of the MLV provirus, which promotes efficient intermolecular
DNA recombination.84 Although essential for PIC integration activ-
ity, interaction with BAF did not explain the MLV integration prefer-
ences. A yeast two-hybrid screen of proteins potentially interacting
with the MLV IN later provided a number of potential binding tar-
gets, many of which were indeed components of active chromatin
and transcription complexes.85 More recent mass spectrometry-based
proteomic analysis of human cellular proteins co-purifying with& Clinical Development Vol. 8 March 2018 35
Figure 4. Overview of the Genomic Characteristics Favoring Gamma-Retroviral Integration
Retroviral integration occurs preferentially in active transcriptional regulatory elements (promoters, enhancers, and super-enhancers), associated to specific histone
modifications (H3K4me1-3, H3K27ac) and bound by histone acetyltransferases and bromodomain/extraterminal domain-containing proteins (CBP/p300, BETs) (see
Figure 2). The dotted line indicates the disassembled nuclear membrane, necessary for the MLV PIC to access chromatin. IN, MLV integrase; MLV, Moloney leukemia virus.
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proteins BRD2, BRD3, and BRD4 as main binding partners of the
viral IN protein86 (Figure 2B). BRD2 was in fact one of the interactors
identified by the yeast two-hybrid screening.85 Enhancers are the
major source of BRD4-dependent transcriptional activation,87 and
genes under the control of super-enhancers are particularly sensitive
to BET inhibition.88
BRD2, BRD3, BRD4, and BRDT belong to the extended BET protein
family that includes BRD1, BRD7, BRD8, and BRD9. BRD2, BRD3,
and BRD4 are ubiquitously expressed, whereas BRDT is only ex-
pressed in the testis. BET proteins have been implicated in transcrip-
tion, DNA replication, and cell-cycle control.89 They exhibit two
N-terminal bromodomains (BD-I and BD-II) that bind acetylated
H3 and H4 tails,90 but not with their unmodified counterparts,91
and two conserved motifs, A and B, which are positively charged
and could contribute to DNA binding.92 The simultaneous binding
to acetylated histone tails and nucleosomal DNA could be a generic
mechanism used by chromatin tethers to achieve tighter and more
specific interactions with chromatin. The conserved C-terminal ex-
tra-terminal (ET) and SEED, Ser/Glu/Asp-rich, domains directly
bind several cellular proteins including transcription factors, chro-
matin-modifying proteins, and histone modification enzymes.89
BET proteins directly bind acetylated histone tails, so their association
with strong enhancers is mediated by direct interactions with
H3K27ac and H3K9ac and/or with other chromatin readers.88 Chro-
matin binding sites of BET proteins have been mapped by chromatin
immunoprecipitation sequencing (ChIP-seq) experiments93 and
show a positive correlation with MLV, but not with HIV-1 or
ASLV ISs.9436 Molecular Therapy: Methods & Clinical Development Vol. 8 March 2Binding of BRD2, BRD3, and BRD4 to theMLV IN is mediated by the
ET domain.86,94,95 Solution NMR and protein interaction studies
showed that the unstructured C-terminal polypeptide (TP) domain
of the MLV IN directly binds the BET ET domain and acquires a sec-
ondary structure upon complex formation.96 Deletion of the TP
domain does not disrupt the catalytic properties of IN but widely al-
ters the MLV targeting profile in human 293T cells, with significantly
reduced association to TSSs, CpG islands, and BRD2, BRD3, and
BRD4 binding sites.96 Downregulation of BET protein expression
by small interfering RNAs (siRNAs), or inhibition of their binding
to chromatin by the small-molecule inhibitor JQ-1, dramatically al-
ters the canonical MLV integration profile in HEK293T cells, with
a dose-dependent, 4-fold reduction of the integrations around
TSSs.94,95 Complementary, genetic evidence for the role of BET asso-
ciation in directing MLV integration was provided by expressing an
artificial LEDGFp75-BET fusion protein in murine NIH 3T3 and hu-
man SupT1 cells, which retargeted MLV integration into actively
transcribed gene bodies, mimicking the HIV-1 integration pattern.86
Overall, these studies demonstrate that BET proteins are the MLV
counterpart of LEDGF/p75 for HIV-1, i.e., specific chromatin tethers
that interact with the PIC by binding the IN and possibly stimulating
its enzymatic function (Figures 2 and 4). Although the interaction of
MLV IN with BET proteins is probably the main determinant of
gamma-retroviral integration target site selection, it is remarkable
that even in the presence of potent inhibitors of BET activity such
as JQ-1, integration at active regulatory elements is still substantially
higher compared to random controls or to HIV-1.95 This suggests
that additional host and/or viral factors may contribute to the integra-
tion preferences of MLV. Early studies with chimeric HIV viruses018
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nents of the PIC, in particular the p12 Gag protein, may have a role
in MLV target site selection.71 The MLV p12 is a constituent of the
PIC, but its function in the complex remains ill-defined. Imaging of
the MLV PIC traffic in live cells allowed the visualization of its dock-
ing to mitotic chromosomes and its release upon exit from mitosis.
Docking occurs concomitantly with the breakdown of the nuclear en-
velope and is impaired in PICs carrying lethal p12 mutations. The
insertion of a heterologous chromatin binding module into p12 re-
stores PIC attachment to chromosomes, confirming the role of p12
as a tethering factor to mitotic chromosomes.97 Later studies, how-
ever, demonstrated that mutations altering the p12 interaction with
chromatin have no detectable effects on the MLV integration
pattern,98 indicating that p12 plays a role in MLV integration by
allowing chromosome association but has no role in the target site
selection process.
Alpha-Retroviruses Integrate Almost Randomly in Mammalian
Cells
ASLV is a member of the alpha-retrovirus family whose natural host
is chicken. The natural viral host tropism can be altered in ASLV-
derived vectors by envelope pseudotyping, in order to efficiently
infect mammalian cells.99 Genome-wide analysis of the integration
pattern of alpha-retroviral vectors in human CD34+ HSPCs revealed
a weak preference for open chromatin regions, as in the case of
gamma-retroviral and LVs, but no bias for transcribed genes or tran-
scriptional regulatory elements, as defined by the epigenetic marks
H3K4me1 andH3K4me3.100 The nearly randomASLV insertion pro-
file in mammals has encouraged the development of optimized vec-
tors as gene transfer tools for gene therapy applications.101 However,
the biology of ASLV-host interaction is much less studied compared
to HIV orMLV, and nothing is known about the viral and cellular de-
terminants of its association to chromatin.
Integration Preferences of Other Retroviruses
The mouse mammary tumor virus (MMTV) is a representative of the
beta-retrovirus family. The only MMTV integration profile so far
described was obtained by a very limited (<500) set of ISs in the
human and murine genomes, essentially from infected mammary
(murine NmuMG and human Hs587T) and non-mammary (HeLa
and HEK293) cell lines. In all cases, MMTV displayed the most
random IS distribution among all known retroviruses, with no pref-
erence for active genes, TSSs, gene-dense regions, CpG islands, or
DNase hypersensitive sites.102,103
The human T cell leukemia virus type 1 (HTLV-1) is the only compo-
nent of the delta-retroviral family for which an integration profile has
been determined to date. Initially, 541 unique HTLV-1 ISs were
cloned and mapped in HeLa cells,5 showing that the virus integrates
into the human genome with a modest though significant preference
for TSSs, transcription units, promoters, and gene-dense regions.
More recent data, obtained from >2,100 ISs of HTLV-1 in the human
Jurkat T cell line, revealed a strong bias for genes, promoters (identi-
fied by CpG islands), and epigenetic marks associated to gene expres-Molecusion control.104 The same pattern was observed in vivo in peripheral
bloodmononuclear cells of HTLV+ patients, but mitigated by a strong
selection against clones harboring a highly expressed provirus oper-
ated by the host immune response against the HTLV-1 infection.104
The human FV is the prototype of the Spumaviridae genus of retro-
viruses. First isolated from a human cell line, it was later reported to
have a chimpanzee origin.105 FV vectors have been designed and
pseudotyped to have a broad host range, large packaging capacity,
and high transduction efficiency in human hematopoietic cells, and
developed as an alternative to MLV vectors for gene therapy of hema-
tological disorders, particularly AIDS.106 Low-resolution profiling of
FV ISs showed integration preferences similar to, though weaker
than, those of MLV for CpG islands and TSSs,107,108 confirmed by
more recent analysis on human HSPCs after transplantation in
immunodeficient mice.109 A study analyzed 139 FV-derived vector
insertion sites recovered ex vivo from human HSPCs after transplan-
tation in NOD/SCID mice, which showed a weak preference for inte-
gration close to oncogenes.110 Given the very small size of the
analyzed samples and the confounding effect of the in vivo selection,
it is difficult to conclude from these studies whether FV may have
evolved a tethering mechanism similar to that of MLV. The FV
Gag contains a C-terminal chromatin-binding site (CBS) that allows
the interaction of PICs with the core histones H2A and H2B on host
chromatin.111 FV PICs can be retargeted to satellite elements and
H3K9me3-positive heterochromatin by modifying the Gag CBS and
the IN proteins,112 indicating that a Gag/IN-based tethering mecha-
nism is most likely at the basis of virus-host interaction also in the
case of spumaviruses.
Conclusions
A large body of studies on the biochemistry and molecular genetics of
retroviral integration has provided a wealth of information on the
remarkably complex and evolved patterns of interactions between
the retroviral integration machinery and the mammalian, and partic-
ularly human, genome. This knowledge has helped in understanding
the basis of the “genotoxic” integration events that caused the occur-
rence of malignant and myelodysplastic proliferation in some gene
therapy trials for inherited blood diseases, and provided clues for
the design of safer gene transfer tools. The current clinical applica-
tions of retroviral gene transfer technology, either ex vivo or in vivo,
involve the transduction of millions of cells, in most cases with stem-
progenitor characteristics, and the generation of a very high number
of potentially mutagenic insertion events. The integration preferences
of each vector type make some of these events more or less likely to
happen, but given the numbers involved, even a completely random
integration machinery would have only a few-fold lower probability
of inducing a potentially oncogenic or otherwise dangerous mutation
than an MLV- or an HIV-based vector. This evidence points to the
design of the vector and the nature of the sequences it carries into
the genome as major factors determining its potential genotoxicity:
replacement of potent, long-range-acting promoter/enhancer ele-
ments of viral origin with constitutive promoters of cellular origin
dramatically reduces the potential mutagenic effect of vectorlar Therapy: Methods & Clinical Development Vol. 8 March 2018 37
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Reviewintegration.113,114 The development of high-throughput technology
for mapping viral ISs in small samples has made long-term moni-
toring of the dynamics of genetically modified cells in patients a real-
ity, increasing the safety of using viral vectors in the clinics while
providing new knowledge on stem cell dynamics.115 Many ap-
proaches have been proposed in the last few years to replace transgen-
esis based on viral INs with more “intelligent”machineries achieving
site-directed rather than semi-random integration, and gene correc-
tion rather than gene addition. Although extremely promising, these
techniques will probably take years before matching the unsurpassed
transduction efficiency of retroviral vectors and becoming practically
applicable in a clinical context. For the time being, improving the
safety profile of retroviral vectors and predicting and evaluating at
best the risks and benefits of each specific therapeutic application
remain the priorities in clinical gene therapy.
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